Racial disparities in survival for patients with clinically localized prostate cancer adjusted for treatment effects

Mayo Clinic Proceedings

Volumn 89, Issue 3, 2014, Pages 300-307

  Tyson II, Mark D ^a   Castle, Erik P ^a  

^a MAYO CLINIC HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AFRICAN AMERICAN; AGED; ARTICLE; ASIAN; CANCER RADIOTHERAPY; CANCER SPECIFIC SURVIVAL; CAUCASIAN; CLINICALLY LOCALIZED PROSTATE CANCER; COHORT ANALYSIS; CONTROLLED STUDY; HEALTH DISPARITY; HISPANIC; HUMAN; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PROSTATE CANCER; RACE DIFFERENCE; RETROSPECTIVE STUDY; UNITED STATES;

AFRICAN AMERICANS; AGED; ASIAN AMERICANS; COHORT STUDIES; COMBINED MODALITY THERAPY; ETHNIC GROUPS; EUROPEAN CONTINENTAL ANCESTRY GROUP; HEALTH STATUS DISPARITIES; HISPANIC AMERICANS; HUMANS; MALE; MIDDLE AGED; MINORITY GROUPS; MINORITY HEALTH; MODELS, STATISTICAL; PROSTATECTOMY; PROSTATIC NEOPLASMS; RETROSPECTIVE STUDIES; RISK ADJUSTMENT; SEER PROGRAM; SURVIVAL ANALYSIS; TREATMENT OUTCOME; UNITED STATES;

EID: 84898610436     PISSN: 00256196     EISSN: 19425546     Source Type: Journal    
DOI: 10.1016/j.mayocp.2013.11.001     Document Type: Article

References (26)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics [published correction appears in CA Cancer J Clin. 2011;61(2):134]. CA Cancer J Clin. 2011;61(2):69-90.
2. Gaziano JM, Sesso HD, Christen WG, et al. Multivitamins in the prevention of cancer in men: the Physicians' Health Study II randomized controlled trial. JAMA. 2012;308(18): 1871-1880.
3. Godley PA, Schenck AP, Amamoo MA, et al. Racial differences in mortality among Medicare recipients after treatment for localized prostate cancer. J Natl Cancer Inst. 2003;95(22):1702-1710.
4. American Cancer Society. Cancer facts and figures 2008. http://www.cancer.org/acs/groups/content/@nho/documents/ document/ 2008cafffinalsecuredpdf.pdf. Accessed June 1, 2013.
5. National Cancer Institute. Surveillance, Epidemiology and End Results (SEER) Program. www.seer.cancer.gov. Accessed June 1, 2013.
6. National Cancer Institute. SEER*Stat software: version 8.0.2. February 19, 2013. Seer.cancer.gov/seersat. Accessed June 1, 2013.
7. Mathur AK, Osborne NH, Lynch RJ, Ghaferi AA, Dimick JB, Sonnenday CJ. Racial/ethnic disparities in access to care and survival for patients with early-stage hepatocellular carcinoma. Arch Surg. 2010;145(12):1158-1163.
8. Du XL, Fang S, Coker AL, et al. Racial disparity and socioeconomic status in association with survival in older men with local/ regional stage prostate carcinoma: findings from a large community-based cohort. Cancer. 2006;106(6):1276-1285.
9. Oakley-Girvan I, Kolonel LN, Gallagher RP, Wu AH, Felberg A, Whittemore AS. Stage at diagnosis and survival in a multiethnic cohort of prostate cancer patients. Am J Public Health. 2003; 93(10):1753-1759.
10. Goggins WB, Wong GK. Poor survival for US Pacific Islander cancer patients: evidence from the Surveillance, Epidemiology, and End Results database: 1991 to 2004. J Clin Oncol. 2007; 25(36):5738-5741.
11. Pienta KJ, Demers R, Hoff M, Kau TY, Montie JE, Severson RK. Effect of age and race on the survival of men with prostate cancer in the Metropolitan Detroit tricounty area, 1973 to 1987. Urology. 1995;45(1):93-101.
12. Lin SS, Clarke CA, Prehn AW, Glaser SL, West DW, O'Malley CD. Survival differences among Asian subpopulations in the United States after prostate, colorectal, breast, and cervical carcinomas. Cancer. 2002;94(4):1175-1182.
13. Robbins AS, Koppie TM, Gomez SL, Parikh-Patel A, Mills PK. Differences in prognostic factors and survival among white and Asian men with prostate cancer, California, 1995-2004. Cancer. 2007;110(6):1255-1263.
14. Robbins AS, Whittemore AS, Thom DH. Differences in socioeconomic status and survival among white and black men with prostate cancer. Am J Epidemiol. 2000;151(4):409-416.
15. Thompson I, Tangen C, Tolcher A, Crawford E, Eisenberger M, Moinpour C. Association of African-American ethnic background with survival in men with metastatic prostate cancer. J Natl Cancer Inst. 2001;93(3):219-225.
16. Robbins AS, Whittemore AS, Van Den Eeden SK. Race, prostate cancer survival, and membership in a large health maintenance organization. J Natl Cancer Inst. 1998;90(13):986-990.
17. Powell IJ, Schwartz K, Hussain M. Removal of the financial barrier to health care: does it impact on prostate cancer at presentation and survival? a comparative study between black and white men in a Veterans Affairs system. Urology. 1995;46(6): 825-830.
18. Tarman GJ, Kane CJ, Moul JW, et al. Impact of socioeconomic status and race on clinical parameters of patients undergoing radical prostatectomy in an equal access health care system. Urology. 2000;56(6):1016-1020.
19. Ward E, Jemal A, Cokkinides V, et al. Cancer disparities by race/ ethnicity and socioeconomic status. CA Cancer J Clin. 2004; 54(2):78-93.
20. Hoffman RM, Gilliland FD, Eley JW, et al. Racial and ethnic differences in advanced-stage prostate cancer: the Prostate Cancer Outcomes Study. J Natl Cancer Inst. 2001;93(5):388-395.
21. Jemal A, Ward E, Wu X, Martin HJ, McLaughlin CC, Thun MJ. Geographic patterns of prostate cancer mortality and variations in access to medical care in the United States. Cancer Epidemiol Biomarkers Prev. 2005;14(3):590-595.
22. Bach PB, Schrag D, Brawley OW, Galaznik A, Yakren S, Begg CB. Survival of blacks and whites after a cancer diagnosis. JAMA. 2002;287(16):2106-2113.
23. Hossain A, Sehbai A, Abraham R, Abraham J. Cancer health disparities among Indian and Pakistani immigrants in the United States: a surveillance, epidemiology, and end results-based study from 1988 to 2003. Cancer. 2008;113(6):1423-1430.
24. Lu-Yao GL, Albertsen PC, Moore DF, et al. Survival following primary androgen deprivation therapy among men with localized prostate cancer [published correction appears in JAMA. 2009;301(1):38]. JAMA. 2008;300(2):173-181.
25. Eastham JA, Kelly WK, Grossfeld GD, Small EJ; Cancer and Leukemia Group B. Cancer and Leukemia Group B (CALGB) 90203: a randomized phase 3 study of radical prostatectomy alone versus estramustine and docetaxel before radical prostatectomy for patients with high-risk localized disease. Urology. 2003;62(suppl 1):55-62.
26. Moul JW, Wu H, Sun L, et al. Early versus delayed hormonal therapy for prostate specific antigen only recurrence of prostate cancer after radical prostatectomy. J Urol. 2004;171(3): 1141-1147.